#United States #Sunnyvale #GRAIL #Galleri #PATHFINDER 2

GRAIL's Groundbreaking Presentations at EDCC and ESMO 2026

GRAIL, Inc., a leading healthcare company dedicated to early cancer detection, is set to present significant data at two prominent global conferences: the Early Detection of Cancer Conference (EDCC) in Edinburgh and the European Society for Medical Oncology (ESMO) Congress in Madrid. Both events, occurring in October 2026, will serve as platforms for unveiling new insights from the NHS-Galleri trial and the PATHFINDER 2 study.

The presentations aim to highlight the continued evolution of GRAIL's innovative Galleri® multi-cancer early detection (MCED) test, which successfully screens for numerous types of cancer, especially those currently lacking effective screening methods. GRAIL's CEO, Dr. Josh Ofman, emphasized the integration of these tests into routine care during his remarks on ongoing analyses indicating promising data for broader multi-cancer detection solutions.

Key Data Presentations at EDCC

GRAIL's presentations at the EDCC will feature six abstracts focused on various aspects of the Galleri test, including:

• - Clinical Performance: A rapid oral presentation will shed light on the efficiency and safety of diagnostic workups guided by Cancer Signal Origin (CSO) methods.
• - Diverse Cancer Detection: A poster will detail the ability of the Galleri test to identify over 200 distinct cancers, including rare forms, showcasing its expansive diagnostic capabilities.
• - Racial and Ethnic Group Insights: GRAIL will present a poster detailing the cancer detection performance of Galleri across different self-reported racial and ethnic populations, aiming to address healthcare disparities.
• - New Findings from NHS-Galleri: A poster will showcase recent findings regarding the preclinical window for cancer detection, supporting the notion that annual MCED screenings can play a crucial role in early diagnosis.
• - Emergency Presentation Reduction: Another poster will highlight how Galleri screenings have substantially decreased emergency cancer diagnoses, indicating its impact on disease management.

Insights at ESMO Congress

Following the EDCC, GRAIL’s focus will shift to the ESMO Congress in Madrid with two primary presentations:

• - Efficiency of Diagnostic Workups: One significant presentation will cover the effectiveness and safety of CSO-guided diagnostic workups post-MCED testing. This oral presentation is expected to provide compelling evidence regarding the Galleri test's performance.
• - Clinical Practice Integration: A poster will discuss the integration of diagnostic workups following positive MCED blood tests within the clinical practice, emphasizing the practical applications of the Galleri test in real-world settings.

The Galleri Test Essentials

The Galleri test stands out as a unique MCED tool developed to screen for more than 50 types of cancer. Notably, it acknowledges the importance of detecting cancers like pancreatic and ovarian, which currently do not have standard screening options. Clinical studies have validated its effectiveness, showing a 20% reduction in Stage IV cancer diagnoses after a year of use. Dr. Ofman noted that such advancements in research data reinforce GRAIL's commitment to changing cancer screening paradigms for better patient outcomes.

GRAIL continues to leverage cutting-edge technology and data analytics, aiming to transform early cancer detection and thereby reduce the global burden of cancer deaths. The information shared at these conferences promises to reflect GRAIL's unwavering commitment to enhancing survival rates through early detection methodologies.

For updates and more insights, keep an eye on GRAIL's official website and social media channels, ensuring ongoing access to the latest breakthroughs in cancer detection technology.